Member Posts > Cardiol Therapeutics to Present Groundbreaking Research in Cardiovascular Therapy at TD Cowen Conference
Cardiol Therapeutics Inc., a clinical-stage biopharmaceutical company dedicated to developing anti-inflammatory and anti-fibrotic therapies for cardiovascular diseases, is set to present at the TD Cowen 45th Annual Health Care Conference in Boston on March 5, 2025, at 11:10 AM EST.
The presentation will focus on the company's latest advancements in cardiac therapies, clinical trial updates, and research findings in inflammatory heart disease treatment. As a leader in the field, Cardiol Therapeutics has been consistently engaging with investors and medical professionals at prestigious conferences.
In February 2025, the company participated in the Oppenheimer 35th Annual Healthcare Life Sciences Conference, where it provided an in-depth look into its clinical pipeline. In September 2023, CEO David Elsley spoke at the Cantor Fitzgerald 2023 Global Healthcare Conference, offering insights into the company's strategic direction and its innovative approach to cardiovascular disease treatment.
By actively participating in these high-profile industry events, Cardiol Therapeutics continues to reinforce its position as a leader in the development of advanced therapies for cardiovascular diseases, ensuring its research is recognized by the global medical community.

#CardiolTherapeutics #CardiovascularResearch #BiotechInnovation #HeartHealth #MedicalBreakthroughs